The Disclosure Code has been approved by the General Assembly on 24 June 2013. The final edited versions of the Code has been submitted to Compliance Committee comments, and has been reviewed by legal counsel.

Advantages for physicians

The overriding principle of ARPharM member companies is transparency. This means that there are clear rules for collaboration with healthcare professionals.

Advantages for patients

Trust is the pillar of every physician-patient relationship. Through transparency in the collaboration among stakeholders in the healthcare field, the patient can be assured that any therapy prescribed by the physician will be useful and geared towards his well-being and not driven by economic interests.

Advantages for the public

Public expectations concerning transparency of the system are ever increasing. In the public eye, the plausibility of all cooperation in the healthcare field is a topic under close scrutiny. The ARPharM Disclosure Code addresses this trend.

Transparency creates trust and combats mistrust!

In November 2013, the ARPharM General Assembly adopted a Disclosure Code, implementing the EFPIA Code of Transparency in collaboration with healthcare professionals.

With the new Code, all future payments in kind by the pharmaceutical industry to physicians and further healthcare professionals, along with organisations in the healthcare field, shall be made public.

Download: Consolidated Code of Ethics of the Research-based Pharmaceutical Industry in Bulgaria.

The comprehensive transparency promotes an even greater strengthening of patient trust in the prescription decisions of the physician.

About Disclosure


The cooperation between pharmaceutical companies and doctors has proven its worth and is already closely controlled by clear guidelines, regulations, and codes. The transparency creates further confidence in already proven partnerships. Through the Disclosure Code, the contributions from ARPharM companies to doctors, healthcare professionals, and organizations become transparent and therefore also traceable.

Read more

News feed

Over 66% of the healthcare professionals in Bulgaria have consented to disclosing their cooperation with pharmaceutical companies within the initiative “Transparency Builds Trust”

In June 2017 for a second consecutive year   the  pharmaceutical industry in Europe disclosed the…

[read more]

Over 60% of the healthcare professionals in Bulgaria have consented to disclosing their cooperation with pharmaceutical companies within the initiative “Transparency builds trust”

On 28.06.2016 the Association of Research-Based Pharmaceutical Companies in Bulgaria (ARPharM) held…

[read more]

ARPharM adopted the Code for Disclosure of Transfers of Value by Pharmaceutical Companies to Healthcare Professionals and Health Organizations

On November 26, 2013 the Association of Research- based Pharmaceutical Manufacturers in Bulgaria (ARPharM)…

[read more]

Disclaimer of liability

Certain links in this website will lead to websites that are not under the control of ARPharM. When you activate these you will leave the ARPharM website. ARPharM has no control over and accepts no liability in respect of materials, data, products or services available on any website which is not under the control of ARPharM.
[read more]